000			02177 a2200673 4500
005			20250517084108.0
264		0	_c20161013
008			201610s 0 0 eng d
022			_a2044-5385
024	7		_a10.1038/bcj.2016.9 _2doi
040			_aNLM _beng _cNLM
100	1		_aBühler, A
245	0	0	_aLenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. _h[electronic resource]
260			_bBlood cancer journal _cMar 2016
300			_ae404 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Heavy Chains _xgenetics
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aLenalidomide
650	0	4	_aLeukemia, Lymphocytic, Chronic, B-Cell _xdiagnosis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aPrognosis
650	0	4	_aRecurrence
650	0	4	_aRetreatment
650	0	4	_aSurvival Analysis
650	0	4	_aThalidomide _xanalogs & derivatives
650	0	4	_aTreatment Outcome
650	0	4	_aTumor Suppressor Protein p53 _xgenetics
700	1		_aWendtner, C-M
700	1		_aKipps, T J
700	1		_aRassenti, L
700	1		_aFraser, G A M
700	1		_aMichallet, A-S
700	1		_aHillmen, P
700	1		_aDürig, J
700	1		_aGregory, S A
700	1		_aKalaycio, M
700	1		_aAurran-Schleinitz, T
700	1		_aTrentin, L
700	1		_aGribben, J G
700	1		_aChanan-Khan, A
700	1		_aPurse, B
700	1		_aZhang, J
700	1		_aDe Bedout, S
700	1		_aMei, J
700	1		_aHallek, M
700	1		_aStilgenbauer, S
773	0		_tBlood cancer journal _gvol. 6 _gp. e404
856	4	0	_uhttps://doi.org/10.1038/bcj.2016.9 _zAvailable from publisher's website
999			_c25818768 _d25818768